Silke Appel-Cresswell
Cited by
Cited by
Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome
AH Evans, R Katzenschlager, D Paviour, JD O'Sullivan, S Appel, ...
Movement disorders: official journal of the Movement Disorder Society 19 (4 …, 2004
Alpha‐synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease
S Appel‐Cresswell, C Vilarino‐Guell, M Encarnacion, H Sherman, I Yu, ...
Movement disorders 28 (6), 811-813, 2013
Compulsive drug use linked to sensitized ventral striatal dopamine transmission
AH Evans, N Pavese, AD Lawrence, YF Tai, S Appel, M Doder, DJ Brooks, ...
Annals of Neurology: Official Journal of the American Neurological …, 2006
The gut microbiome in human neurological disease: a review
H Tremlett, KC Bauer, S Appel‐Cresswell, BB Finlay, E Waubant
Annals of neurology 81 (3), 369-382, 2017
Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease
AH Evans, AD Lawrence, J Potts, S Appel, AJ Lees
Neurology 65 (10), 1570-1574, 2005
DNAJC13 mutations in Parkinson disease
C Vilariño-Güell, A Rajput, AJ Milnerwood, B Shah, C Szu-Tu, J Trinh, I Yu, ...
Human molecular genetics 23 (7), 1794-1801, 2014
Imaging of compensatory mechanisms in Parkinson's disease
S Appel-Cresswell, R de la Fuente-Fernandez, S Galley, MJ McKeown
Current opinion in neurology 23 (4), 407-412, 2010
Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti‐reward
AH Evans, AD Lawrence, SA Cresswell, R Katzenschlager, AJ Lees
Movement Disorders 25 (7), 867-876, 2010
Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial
RB Postuma, J Anang, A Pelletier, L Joseph, M Moscovich, D Grimes, ...
Neurology 89 (17), 1795-1803, 2017
Global investigation and meta-analysis of the C9orf72 (G4C2) n repeat in Parkinson disease
J Theuns, A Verstraeten, K Sleegers, E Wauters, I Gijselinck, S Smolders, ...
Neurology 83 (21), 1906-1913, 2014
Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease
A Garg, S Appel-Cresswell, K Popuri, MJ McKeown, MF Beg
Frontiers in neuroscience 9, 101, 2015
DNAJC13 genetic variants in parkinsonism
EK Gustavsson, J Trinh, I Guella, C Vilariño‐Güell, S Appel‐Cresswell, ...
Movement disorders 30 (2), 273-278, 2015
Microbiota composition and metabolism are associated with gut function in Parkinson's disease
MS Cirstea, AC Yu, E Golz, K Sundvick, D Kliger, N Radisavljevic, ...
Movement Disorders 35 (7), 1208-1217, 2020
The protective effect of LRRK2 p. R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants
MG Heckman, A Elbaz, AI Soto-Ortolaza, DJ Serie, JO Aasly, G Annesi, ...
Neurobiology of aging 35 (1), 266. e5-266. e14, 2014
Canadian guideline for Parkinson disease
D Grimes, M Fitzpatrick, J Gordon, J Miyasaki, EA Fon, M Schlossmacher, ...
Cmaj 191 (36), E989-E1004, 2019
Gender differences in Parkinson's disease depression
AJ Perrin, E Nosova, K Co, A Book, O Iu, V Silva, C Thompson, ...
Parkinsonism & related disorders 36, 93-97, 2017
DCTN1 p. K56R in progressive supranuclear palsy
EK Gustavsson, J Trinh, I Guella, C Szu-Tu, J Khinda, CH Lin, RM Wu, ...
Parkinsonism & related disorders 28, 56-61, 2016
Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease
ME Gonzalez, K Dinelle, N Vafai, N Heffernan, J McKenzie, ...
Neuroimage 68, 11-21, 2013
Parkinsonism in GTP cyclohydrolase 1 mutation carriers
I Guella, HE Sherman, S Appel-Cresswell, A Rajput, AH Rajput, MJ Farrer
Brain 138 (5), e349, 2015
Medical management of Parkinson’s Disease after initiation of deep brain stimulation
A Fasano, S Appel-Cresswell, M Jog, M Zurowkski, S Duff-Canning, ...
Canadian Journal of Neurological Sciences 43 (5), 626-634, 2016
The system can't perform the operation now. Try again later.
Articles 1–20